Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...
MarketBeat on MSN50m
MarketBeat Week in Review – 02/10 - 02/14
If you believe in the Efficient Market hypothesis, you had a good week. Despite a hotter-than-expected CPI print, a rise in credit card delinquencies, and the Trump administration’s announcement of 25 ...
Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon
In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...